BRPI0509754A - inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante - Google Patents

inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante

Info

Publication number
BRPI0509754A
BRPI0509754A BRPI0509754-1A BRPI0509754A BRPI0509754A BR PI0509754 A BRPI0509754 A BR PI0509754A BR PI0509754 A BRPI0509754 A BR PI0509754A BR PI0509754 A BRPI0509754 A BR PI0509754A
Authority
BR
Brazil
Prior art keywords
inhibitors
treatment
protein kinase
transplant rejection
autoimmune diseases
Prior art date
Application number
BRPI0509754-1A
Other languages
English (en)
Inventor
Juergen Wagner
Walter Schuler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408066A external-priority patent/GB0408066D0/en
Priority claimed from GB0414540A external-priority patent/GB0414540D0/en
Priority claimed from GB0422068A external-priority patent/GB0422068D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0509754A publication Critical patent/BRPI0509754A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE PROTEìNA QUINASE C PARA O TRATAMENTO DE DOENçAS AUTO-IMUNES E DE REJEIçãO A TRANSPLANTE. A presente invenção refere-se ao uso de um composto de fórmula I, II, II ou IV, como descrito no relatório, em transplante e doenças auto-imunes.
BRPI0509754-1A 2004-04-08 2005-04-07 inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante BRPI0509754A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0408066A GB0408066D0 (en) 2004-04-08 2004-04-08 Organic compounds
GB0414540A GB0414540D0 (en) 2004-06-29 2004-06-29 Organic compounds
GB0422068A GB0422068D0 (en) 2004-10-05 2004-10-05 Organic compounds
PCT/EP2005/003663 WO2005097108A1 (en) 2004-04-08 2005-04-07 Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection

Publications (1)

Publication Number Publication Date
BRPI0509754A true BRPI0509754A (pt) 2007-10-16

Family

ID=34966151

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509754-1A BRPI0509754A (pt) 2004-04-08 2005-04-07 inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante

Country Status (7)

Country Link
US (1) US20070232658A1 (pt)
EP (1) EP1734952A1 (pt)
JP (1) JP2007532506A (pt)
AU (1) AU2005230399B2 (pt)
BR (1) BRPI0509754A (pt)
CA (1) CA2560311A1 (pt)
WO (1) WO2005097108A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070086A2 (en) 2004-01-21 2005-08-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
CA2658835A1 (en) * 2006-08-23 2008-02-28 Novartis Ag Use of pkc inhibitors in ocular diseases
AU2007333313A1 (en) * 2006-12-07 2008-06-19 Novartis Ag Use of PKC inhibitors in transplantation
WO2010021696A1 (en) * 2008-08-18 2010-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
ES2492498T3 (es) 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
JP5781943B2 (ja) * 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
WO2010096160A1 (en) * 2009-02-17 2010-08-26 The Board Of Trustees Of The Leland Stanford Junior University Compartment-specific non-hla targets for diagnosis and prediction of graft outcome
WO2010123119A1 (ja) * 2009-04-23 2010-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性腸疾患治療剤およびそのスクリーニング方法
EP2507630B1 (en) 2009-12-02 2017-01-25 The Board of Trustees of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
WO2011119980A1 (en) 2010-03-25 2011-09-29 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
US8962261B2 (en) 2011-04-06 2015-02-24 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for IGA nephropathy
WO2013138568A1 (en) 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
CN104203951B (zh) 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CN108135875B (zh) 2015-07-31 2021-12-31 约翰霍普金斯大学 用于治疗代谢重编程病症的方法和组合物
EA034571B1 (ru) 2015-07-31 2020-02-21 Дзе Джонс Хопкинс Юниверсити Пролекарства аналогов глутамина
US11185534B2 (en) 2017-02-01 2021-11-30 The Johns Hopkins University Prodrugs of glutamine analogs
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
SE9603284D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
US6284783B1 (en) * 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
EP2070921A1 (en) * 2000-11-07 2009-06-17 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
TW200918046A (en) * 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
EP1513830A1 (en) * 2002-06-05 2005-03-16 Janssen Pharmaceutica N.V. Bisindolyl-maleimid derivatives as kinase inhibitors

Also Published As

Publication number Publication date
AU2005230399B2 (en) 2009-07-09
WO2005097108A1 (en) 2005-10-20
US20070232658A1 (en) 2007-10-04
EP1734952A1 (en) 2006-12-27
CA2560311A1 (en) 2005-10-20
JP2007532506A (ja) 2007-11-15
AU2005230399A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
BRPI0509754A (pt) inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante
BRPI0611863A2 (pt) composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo
CL2011000285A1 (es) Compuestos derivados de 1-(het)aril-4-fenil-pirazoles; uso de dichos compuestos para combatir plagas de animales; procedimiento para combatir plagas de animales; procedimiento para la preparación de composiciones agroquímicas, y compuestos intermediarios.
UY30816A1 (es) Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
BR112012019437A2 (pt) 5-alquinil-pirimidinas
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
EA200870116A1 (ru) Бициклические гетероарильные соединения
CR20110230A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
GEP20104974B (en) Carbonylamino pyrrolopyrazoles, protent kinase inhibitors
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
NI201100063A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.